ArticleOncotarget2020

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.

Sunkyu Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.